.png){kind=icon}
返回
Cell microarray platform for anticancer drug development
.png){kind=icon}
PRE
AI
DOI：10.1002/ddr.20183.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Pharmacodynamic assessment of whether a drug has interacted with and modified its target is an essential component of molecularly targeted clinical trials. Although many trials are written with the intent to assess tumor biopsies, if available, thus far the great majority of early drug trials have used peripheral blood mononuclear cells (PBMC) as a tumor surrogate. Typically, PBMC are studied by low-throughput techniques such as Western blot. We present the use of a cell-based tissue microarray for assessment of anticancer drug activity in vivo. We demonstrate the utility of this technique for analysis of protein hyperacetylation in response to treatment with the histone deacetylase inhibitor, SNDX-275 in PBMC treated in vitro and in PBMC and bone marrow aspirates from patients in Phase I clinical trials with SNDX-275. We demonstrate that the cell microarray can be used to measure drug response in a high-throughput manner, allowing analysis of an entire trial on one or two glass slides. The cell microarray technique brings the advantages of the tissue microarray platform to the pharmacodynamic assessment of single cells, such as those isolated from bone marrow aspirates, fine needle aspirates, or malignant effusions, and to analysis of PBMC, the most commonly studied surrogate in oncology trials.
Keyword:
pharmacodynamic
tissue microarray
histone deacetylase inhibitor
high-throughput
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
4.2
论文数:
2.9K
被引数:
3.6K
机构
引用论文
Circulating tumor cells (CTC) detection: Clinical impact and future directions循环肿瘤细胞 (CTC) 检测: 临床影响和未来方向.png)
CANCER LETTERS
CANCER LETTERSIF10.1
PREAI
分享收藏QUANTITATIVE ANALYSIS OF TAPHOFACIES AND PALEOCOMMUNITIES IN THE EARLY CAMBRIAN CHENGJIANG LAGERSTATTEPALAIOS
PALAIOSIF0
PREAI
分享收藏MS-275, a potent orally available inhibitor of histone deacetylases - The development of an anticancer agentMS-275，一种有效的口服组蛋白去乙酰化酶抑制剂-抗癌剂的开发
PREAI
分享收藏
查看更多内容